Vantive Becomes Independent, Focuses on Vital Organ Therapies

Vantive, formerly part of Baxter’s renal care division, has officially launched as an independent company specializing in therapies for vital organs. The transition follows the completion of its acquisition from Baxter by investment funds managed by Carlyle. With a 70-year history in renal care innovation, Vantive aims to enhance treatment options for patients and healthcare professionals worldwide.

"From patients beginning dialysis treatment to professionals working in intensive care units, timely access to the right therapy is essential. Our objective is to expand options, increase control, and create more opportunities for better outcomes," says Chris Toth, CEO, Vantive.

The company seeks to improve standards in renal and vital organ therapies, addressing a global need for better access to care. An estimated 4 million people receive dialysis for chronic kidney disease, though access varies significantly by region. Patients undergoing dialysis often face physical and emotional challenges throughout their treatment. Vantive’s goal is to reduce barriers to therapy initiation and maintenance, allowing more patients to receive consistent, effective care.

Vantive provides a range of products, digital solutions, and services designed to support home and in-clinic dialysis, as well as critical care therapies in intensive care units. Operating in over 100 countries, the company facilitates more than a million patient interactions daily, underscoring its global reach and commitment to improving healthcare delivery. Toth highlights the role of Vantive’s 23,000 employees in delivering innovative solutions that impact millions of patients and their families.

“Our new brand is coming to life through our teams’ steadfast commitment to helping patients lead full and meaningful lives in partnership with our healthcare customers. We are eager to continue collaborating with the kidney and critical care communities to help transform care,” says Toth.